Buscar
Congreso SOLACI
Home Tags Apixaban

Tag: apixaban

apixaban en fibrilacion auricular tavi

Use of Apixaban and Post TAVR Valve Thrombosis

solaci - 0
AHA 2023

AHA 2023 | Use of Apixaban for Stroke Prevention in Subclinical...

solaci - 0
apixaban en fibrilacion auricular tavi

Apixaban and Valve Thrombosis after TAVR

solaci - 0
terapia antitrombótica triple

Are Antithrombotics Necessary in Outpatients after COVID-19?

solaci - 0
ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

solaci - 0
ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

solaci - 0
ACC Virtual 2020 | CARAVAGGIO: Apixaban en tromboembolismo venoso asociado al cáncer

Virtual ACC 2020 | CARAVAGGIO: Apixaban in Venous Thromboembolism Associated to...

solaci - 0
anticoagulated patients that receive angioplasty

Benefit of Anticoagulation in the Elderly with Atrial Fibrillation

solaci - 0
ACC 2019 | POET: los antibióticos vía oral con buenos resultados a largo plazo en endocarditis

ACC 2019 | AUGUSTUS: Apixaban Plus P2Y12 Inhibitor Is the Best Combination...

solaci - 0
apixaban en fibrilacion auricular tavi

Apixaban: An Alternative for Patients with Atrial Fibrillation Undergoing TAVR?

solaci - 0

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Dr. Juan Manuel Pérez - 0
Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Dr. Juan Manuel Pérez - 0
Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Dr. Omar Tupayachi - 0
Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

Noticias Institucionales

SELUTION Sirolimus-Eluting Balloon For De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
The Latin American Society of Interventional Cardiology invites you to join a new virtual scientific event focused on the latest evidence and clinical perspectives...

SOL SOLACI performed a new procedure in Argentina using bioabsorbable stents in pulmonary branches

solaci - 0
The SOLACI Solidarity Program carried out a new procedure on a patient from the region of Frías, in Santiago del Estero (Argentina), during October...

Venezuela 2025 Sessions | Young Interventional Cardiologists Contest

solaci - 0
Call for Case Submissions LIII SOLACI Regional Sessions – 18th Andean Region We invite all young Latin American cardiologists to submit clinically relevant interventional cardiology cases...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad